Immunovant shares plunge after phase 3 trials fails to meet primary endpoint
Go back to Immunovant shares plunge after phase 3 trials fails to meet primary endpoint| (NASDAQ: IMVT) | Delayed: 32.67 +1.52 (4.88%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $31.15 | 52 Week High | $ | |||
| Open | $31.31 | 52 Week Low | $ | |||
| Day High | $32.89 | P/E | N/A | |||
| Day Low | $31.05 | EPS | $ | |||
| Volume | 1,343,395 | |||||
